CELLECTIS
Cellectis is a biotechnology company that uses advanced genetic engineering techniques to develop immunotherapies for cancer.
Price history of CELLECTIS
Price history of CELLECTIS
Performance & Momentum
Strategic Analysis
CELLECTIS • 2026
Cellectis is a French biotechnology company specializing in gene editing applied to oncology, with an investment thesis centered on the development of innovative immunotherapies against cancer. Its positioning is based on disruptive technology and the potential value of its clinical programs, rather than on a mature commercial business model.
- Recognized expertise in genetic engineering and strong technological differentiation
- Exposure to a high-potential therapeutic area, oncology, where innovation can create significant value
- Speculative profile offering upside leverage in the event of clinical or regulatory progress
- High dependence on clinical outcomes and regulatory milestones, with limited commercial visibility
- Very uneven stock-market history, indicating strong sensitivity to dilution risk and pipeline disappointments
Momentum appears intermediate, with a recent trend that remains mixed despite a pronounced rebound over the past year. The profile remains that of a volatile biotech stock: investor interest can increase rapidly on positive clinical news, but the trajectory remains fragile in the absence of visible catalysts.
Similar stocks to CELLECTIS
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
